RadioMedix (225Ac-PSMA I&T Program) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
RadioMedix (225Ac-PSMA I&T Program) General Information
Description
225Ac-PSMA I&T Asset, a targeted alpha therapy (TAT) for metastatic castration-resistant prostate cancer program located in Houston, Texas.
Contact Information
Corporate Office
- Houston, TX
- United States
Corporate Office
- Houston, TX
- United States
RadioMedix (225Ac-PSMA I&T Program) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
RadioMedix (225Ac-PSMA I&T Program) Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
RadioMedix (225Ac-PSMA I&T Program) FAQs
-
Where is RadioMedix (225Ac-PSMA I&T Program) headquartered?
RadioMedix (225Ac-PSMA I&T Program) is headquartered in Houston, TX.
-
What industry is RadioMedix (225Ac-PSMA I&T Program) in?
RadioMedix (225Ac-PSMA I&T Program)’s primary industry is Buildings and Property.
-
Is RadioMedix (225Ac-PSMA I&T Program) a private or public company?
RadioMedix (225Ac-PSMA I&T Program) is a Private company.
-
What is RadioMedix (225Ac-PSMA I&T Program)’s current revenue?
The current revenue for RadioMedix (225Ac-PSMA I&T Program) is .
-
Who are RadioMedix (225Ac-PSMA I&T Program)’s investors?
RadioMedix has invested in RadioMedix (225Ac-PSMA I&T Program).
-
When was RadioMedix (225Ac-PSMA I&T Program) acquired?
RadioMedix (225Ac-PSMA I&T Program) was acquired on 13-Feb-2023.
-
Who acquired RadioMedix (225Ac-PSMA I&T Program)?
RadioMedix (225Ac-PSMA I&T Program) was acquired by Fusion Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process